Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Gauthier, Serge; Feldman, Howard H; Schneider, Lon S; Wilcock, Gordon K; Frisoni, Giovanni; Hardlund, Jiri H; Moebius, Hans J; Bentham, Peter; Kook, Karin A; Wischik, Damon J; Schelter, Bjoern O; Davis, Charles S; Staff, Roger T; Bracoud, Luc; Shamsi, Kohkan; Storey, John M D; Harrington, Charles R; Wischik, Claude M

doi:10.1016/S0140-6736(16)31275-2

Scientific article

English

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

ContributorsGauthier, Serge; Feldman, Howard H; Schneider, Lon S; Wilcock, Gordon K; Frisoni, Giovanni; Hardlund, Jiri H; Moebius, Hans J; Bentham, Peter; Kook, Karin A; Wischik, Damon J; Schelter, Bjoern O; Davis, Charles S; Staff, Roger T; Bracoud, Luc; Shamsi, Kohkan; Storey, John M D; Harrington, Charles R; Wischik, Claude M

Published inLancet, vol. 388, no. 10062, p. 2873-2884

Publication date2016

Abstract

Leuco-methylthioninium bis(hydromethanesulfonate; LMTM), a stable reduced form of the methylthioninium moiety, acts as a selective inhibitor of tau protein aggregation both in vitro and in transgenic mouse models. Methylthioninium chloride has previously shown potential efficacy as monotherapy in patients with Alzheimer's disease. We aimed to determine whether LMTM was safe and effective in modifying disease progression in patients with mild to moderate Alzheimer's disease.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de psychiatrie

Research groups

Troubles de mémoire et maladie d'Alzeimer (935)

Citation (ISO format)

GAUTHIER, Serge et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. In: Lancet, 2016, vol. 388, n° 10062, p. 2873–2884. doi: 10.1016/S0140-6736(16)31275-2

Article (Published version)

Identifiers

PID : unige:95090
DOI : 10.1016/S0140-6736(16)31275-2
PMID : 27863809

Journal ISSN0140-6736

539views

0downloads

Creation08/06/2017 13:21:00

First validation08/06/2017 13:21:00

Update15/03/2023 01:48:19

Status update15/03/2023 01:48:18

Last indexation31/10/2024 07:14:43

Archive ouverte UNIGE

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Technical informations